Setting a new standard for long-term survival in metastatic kidney cancer

Cancer. 2022 Jun 1;128(11):2058-2060. doi: 10.1002/cncr.34177. Epub 2022 Apr 5.

Authors

Matthew K Labriola^{1

2}, Daniel J George^{1

2}

Affiliations

¹ Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina.
² Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.

PMID: 35383907
DOI: 10.1002/cncr.34177

No abstract available

Keywords: conditional survival; immunotherapy; prognosis; renal cell carcinoma; risk stratification.

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Renal Cell* / pathology
Female
Humans
Immunotherapy
Kidney Neoplasms* / pathology
Male
Prognosis

Associated data

ClinicalTrials.gov/NCT02231749
ClinicalTrials.gov/NCT03937219
ClinicalTrials.gov/NCT03793166